Immunogenicity of T790M-5 and T790M-7 peptides in NSCLC patients treated with EGFR-TKIs.

Abbreviations: M, male; F, female; PR, partial response; SD, stable disease; PD, progressive disease.aPrimary clinical responses to EGFR-TKIs.bTreatment with EGFR-TKIs was ongoing in the EGFR-TKI-sensitive patients at the time of blood sampling.cThe period (days) between discontinuance of EGFR-TKI-treatment and blood sampling.dSpot numbers (/2×104 cells) by ELISPOT assay.eT790M mutation examined by droplet digital PCR in cell-free DNA from plasma.